Scott R, Parker H, Mccartney S, Harrow P, Williams D, Giles I. Outcomes following biosimilar TNF inhibitors use for inflammatory-mediated immune disorders in pregnancy.
Obstet Med 2021;
15:104-107. [PMID:
35845229 PMCID:
PMC9277732 DOI:
10.1177/1753495x211028779]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Revised: 05/15/2021] [Accepted: 06/09/2021] [Indexed: 12/03/2022] Open
Abstract
Background
Biosimilar tumour necrosis factor inhibitors (TNFi) are increasingly used to
treat inflammatory immune-mediated disorders as they cost less than the
originator biologic drug. More women are therefore becoming pregnant on
biosimilar TNFi. This is the first paper to explore the safety and efficacy
of biosimilar therapies in pregnancy.
Methods
A retrospective review of clinical data reviewed pregnancy outcomes and
inflammatory disease activity in 18 pregnancies where the mother was using a
biosimilar TNFi at conception.
Results
Biosimilar therapy was not associated with congenital abnormalities, preterm
birth or other adverse pregnancy outcomes. Stopping biosimilar TNFi in
pregnancy was associated with childbirth at an earlier gestation, as well as
a flare of inflammatory disease in pregnancy or post-partum.
Conclusions
Women and clinicians should feel confident in using biosimilar TNFi in early
pregnancy, and continuing them through pregnancy to prevent flares in late
pregnancy or the early post-partum.
Collapse